The present invention describes the use of compounds and combinations thereof which inhibit the phosphatidic acid phosphohydrolase enyzme (PAP) for producing medicines that can be used to treat cancer; PAP inhibitors are used to block the progression of cancers that depend on the epidermal growth factor receptor (EGFR) oncogenic variants thereof and other members of the ErbB family by inducing the endocytosis thereof and thus making them inaccessible to stimuli which promote cancer survival and ...

A transdermal d propranolol or racemic propranolol patch for use as an adjunct to surgery in the treatment of malignant melanoma and/or tattoo related applications are herein disclosed.

The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

A unit dosage form such as a capsule or the like for delivering drugs into the body in a sustained release fashion similar to that produced by INDERAL® LA indicated for the treatment of cardiovascular diseases comprises two populations of propranolol-containing particles (beads pellets granules etc.). Each bead population exhibits a pre-designed rapid release profile (i.e. substantially complete release within 60 minutes) or sustained release profile over a period of 24 hours. Such a cardiovascu...